Technical Analysis for MDFZF - Medifocus Inc

Grade Last Price % Change Price Change
grade F 0.0033 0.00% 0.0000
MDFZF closed unchanged on Wednesday, October 16, 2019, on 21 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MDFZF trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%

Older signals for MDFZF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a leader in the use of focused microwave energy to treat cancer and other tumors. It owns two fully developed technology platforms with comprehensive US and international patent protection: (1) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (?BPH?) was developed based on the Endo-thermotherapy and is currently generating revenue, and (2) The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company?s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.
Medicine Health RTT Medical Specialties Cancer Microwave Fda Tumor Food And Drug Administration Radiation Therapy Technology Platforms Catheter Tumors Benign Prostatic Hyperplasia Bph Mit Thermotherapy Treatment Of Benign Prostatic Hyperplasia
Is MDFZF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.0514
52 Week Low 0.0023
Average Volume 193,895
200-Day Moving Average 0.0231
50-Day Moving Average 0.0153
20-Day Moving Average 0.0071
10-Day Moving Average 0.0045
Average True Range 0.0022
ADX 35.23
+DI 21.5569
-DI 48.503
Chandelier Exit (Long, 3 ATRs ) 0.01
Chandelier Exit (Short, 3 ATRs ) 0.0089
Upper Bollinger Band 0.0147
Lower Bollinger Band -0.0005
Percent B (%b) 0.25
BandWidth 214.084507
MACD Line -0.0037
MACD Signal Line -0.0037
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0036
Resistance 3 (R3) 0.0036 0.0036 0.0036
Resistance 2 (R2) 0.0036 0.0035 0.0036 0.0035
Resistance 1 (R1) 0.0034 0.0034 0.0034 0.0034 0.0035
Pivot Point 0.0034 0.0034 0.0034 0.0034 0.0034
Support 1 (S1) 0.0032 0.0033 0.0032 0.0032 0.0031
Support 2 (S2) 0.0032 0.0032 0.0032 0.0031
Support 3 (S3) 0.0030 0.0032 0.0031
Support 4 (S4) 0.0030